B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $396
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $364 to $396.
B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $364 to $396.